GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2 registry-linked trialsAbstract readPractice Guideline
In one paragraph
Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 358 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
358citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continued PD-L1 Inhibition With Atezolizumab With Rechallenge Chemotherapy in Patients With Sensitive Relapse SCLC Progressing on First-line Platinum-etoposide Chemotherapy and a PD-L1 Inhibitor: CARRY-ON Study-GOIRC-01-2023
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer: A Prospective, Non-interventional Study
Who cites it
358 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis.JAMA network open · 2026Pooled it
- Pooled it
- Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects.Oncology research · 2026Pooled it
- Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- Prognostic value of baseline LIPI, LDH and dNLR in ES-SCLC patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.BMC cancer · 2024Pooled it
- Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).Journal for immunotherapy of cancer · 2026Trial
- Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.Advances in therapy · 2026Trial
- Malignancy Detection Rates of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Trial
- Trial
- Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Cancer science · 2025Trial
- Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.Journal for immunotherapy of cancer · 2025Trial
- Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial.Cancer immunology, immunotherapy : CII · 2025Trial
- Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.Oncoimmunology · 2026Article
- Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.British journal of cancer · 2026Article
- AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.International journal of clinical oncology · 2026Article
- Comparison of Diagnostic Performance of Whole-Body 360° CZT Bone SPECT/CT and Planar Bone Scintigraphy in Detecting Bone Metastasis in Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Lung Cancer Survivorship: Challenges and Care Needs.Cancers · 2026Review
298 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
A-M C DingemansDepartment of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
M FrühDepartment of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, University of Bern, Bern, Switzerland.
A ArdizzoniDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
B BesseGustave Roussy, Cancer Medicine Department, Villejuif, France; Paris-Saclay University, Orsay, France.
C Faivre-FinnDivision of Cancer Sciences, University of Manchester & The Christie, NHS Foundation Trust, Manchester, UK.
L E HendriksDepartment of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
S LantuejoulDepartment of Biopathology, Centre Léon Bérard, Grenoble Alpes University, Lyon, France.
S PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
N ReguartDepartment of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
C M RudinMemorial Sloan Kettering Cancer Center, New York, USA.
D De RuysscherDepartment of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
P E Van SchilDepartment of Thoracic and Vascular Surgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
J VansteenkisteDepartment of Respiratory Oncology, University Hospital KU Leuven, Leuven, Belgium.
M ReckLungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaFollow-Up StudiesHumansClinical Practice Guidelinesdiagnosisfollow-upsmall-cell lung cancertreatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06663098ClinicalTrials.gov
NCT07026669ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.